Given that β-catenin interacts with AR or TCF to activate AR or Wnt/β-catenin-responsive transcription, respectively, in prostate cancer [33, 34], we examined the β-catenin occupancy on AR and TCF binding sites using chromatin immunoprecipitation (ChIP) assays. This evidence concerns the gene AR and prostate carcinoma.